Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
ALFAURUS : A DB Randomized Parallel Group Study of Alfuzosin 10mg OD vs Placebo in the Management of AUR in Patients With a 1st Episode Due to BPH
- Conditions
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 800
- Registration Number
- NCT00290030
Glulisine Pre- and Postmeal
- Conditions
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2010-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 20
- Registration Number
- NCT00290043
Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)
- Conditions
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2009-04-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 368
- Registration Number
- NCT00288236
- Locations
- 🇬🇧
Sanofi-Aventis, Guildford, United Kingdom
Telithromycin in Acute Exacerbation of Chronic Bronchitis
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2009-12-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 54
- Registration Number
- NCT00288223
- Locations
- 🇹🇷
Sanofi-Aventis, Istanbul, Turkey
Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease
- Conditions
- First Posted Date
- 2006-02-01
- Last Posted Date
- 2008-12-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 390
- Registration Number
- NCT00285077
- Locations
- 🇸🇪
Sanofi-Aventis Administrative Office, Bromma, Sweden
Study of the Effect of SR57667B in Patients With Alzheimer's Disease
- Conditions
- First Posted Date
- 2006-02-01
- Last Posted Date
- 2006-02-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 500
- Registration Number
- NCT00285025
Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2006-01-31
- Last Posted Date
- 2012-12-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 98
- Registration Number
- NCT00284141
- Locations
- 🇫🇷
Sanofi-Aventis Administrative Office, Paris, France
AVE7688 in Patients With Mild to Moderate Blood Pressure
- First Posted Date
- 2006-01-31
- Last Posted Date
- 2016-05-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1940
- Registration Number
- NCT00284128
- Locations
- 🇹🇷
Sanofi-Aventis Administrative Office, Istanbul, Turkey
Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo
- Conditions
- First Posted Date
- 2006-01-30
- Last Posted Date
- 2008-04-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 36
- Registration Number
- NCT00283790
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
APROVE : Irbesartan in Hypertension
- Conditions
- First Posted Date
- 2006-01-27
- Last Posted Date
- 2008-04-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 200
- Registration Number
- NCT00283036
- Locations
- 🇩🇿
Sanofi-Aventis, Alger, Algeria